Sai Life Sciences Ltd Q4 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/kesu4apwxkapi3d9qjjmg0f8.pdf

Key Takeaways


CDMO: Commercial Scale-Up and Pipeline Depth

Krishna Kanumuri: "we're the only company really stitched all these together and we're approved by all three of these areas. And that's the strength why we believe that we can retain a majority of the molecules, but that said, some molecules definitely leak out of us... the chances of us retaining are higher than most other players at this point." [8-9]

CRO: Large Pharma Influx and Biotech Recovery

Krishna Kanumuri: "I think large pharma is very clear that they want to build the India footprint. I think the large pharma business did not exist in India a couple of years ago. There were only two, three large pharma who were actively doing med-chem in India, I would say as close as three years back. But now every large pharma is looking at coming to India to do discovery."

New Modalities: Episodic Revenue, Capability Build Underway

Krishna Kanumuri: "The important part of being a CRO, in our opinion, is to be a fast follower, be close enough to be able to change the trend, but not be on the bleeding edge where you're left with the dead investment."

Margins: Guardrails, Dilution, and the Capex Cycle

Siva Chittor: "with pharma generally there's an open-book pricing and from what we've seen, and we've seen this across the Chinese companies operating at much larger scale, the margins tend to remain between the 25% to 30%, which is what we've seen and our pricing with pharma indicates that a 28% to 30% is much more comfortable from a pharma pricing perspective."

AI and Technology: Embedded, Not Disruptive

Krishna Kanumuri: "I think end of the day the synthesis part does not change, and the AI moieties are much more complex to make than regular synthesis. Yes, you might make fewer molecules, but the resources needed to make the molecule are more than the past... I think net-net, I think my view of AI is going to be that you probably won't drop the R&D dollars, you probably will do more with less to have more targets."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth15% to 20% CAGR on current revenue run rate of ~₹2,200 crOver a three-year period
EBITDA margin28% to 30% steady-state2–3 years
FY27 H2 stronger than H1Second half stronger due to new capacities and investments coming on streamFY27
FY27 capexINR1,100–1,300 cr (65% CDMO, 35% CRO; 75% capacity, 25% capability/AI)FY27
Capacity expansion225 KL of 450 KL addition online; majority of plant capex in FY27H2 FY27
New commercial productsAt least a couple begin production and commercial revenueFY27
Net asset turn1.2x to 1.4x, with a dip before recovery due to capex cycleMedium-term
Biotech recoveryBiotech segment expected to pick upNext 24 months
AI/digital embeddingAI and digital increasingly embedded across core scientific and development workflows18–24 months

Key Metrics

MetricQ4 FY26
Revenue growth (FY26)29%, vs 16% in FY25
EBITDA growth (FY26)56%
PAT growth (FY26)109%
EBITDA margin (FY26)30%, achieved; steady-state aspiration 28% to 30%
CRO segment growth (FY26)24%
CDMO segment growth (FY26)33%
Revenue growth aspiration15% to 20% over a three-year period
EBITDA margin aspiration28% to 30% over a three-year period
FY27 capex estimate₹1,100 cr to ₹1,300 cr, split CDMO 65%, CRO 35%
FY26 capex₹633 cr against budgeted ₹700 cr
Commercial molecules34, up from 30 in Q3 FY26
Phase III/pre-registration molecules11, up from ~6 in Q3 FY26
Revenue from top 19 pharma clients49% of FY26 revenue, up from 28% in FY22
Top 10 customer concentration54% of FY26 revenue
Top 5 customer concentration37% of FY26 revenue
Top 1 customer concentration12% of FY26 revenue
CRO revenue mix (pharma vs biotech)48% vs 52%
H1/H2 revenue split (FY26)48% / 52%, vs 40%/60% in FY25
Q4 share of FY26 revenue27%, vs 34% in Q4 FY25
New technology revenue salience4%, down from 7%
Asset turn (net basis) medium-term commitment1.2x to 1.4x
Current capacity (Bidar)~1,150 KL
Capacity expansion underway700 KL to 1,150 KL, 225 KL expected this year, 225 KL next year
Capex allocation: capacity expansion75% of FY27 capex
Capex allocation: capability, AI and technology25% of FY27 capex
Biotech funding YTD growth52% YoY
April 2026 biotech funding$10.6 bn, up over 4% YoY